logo
  Join        Login             Stock Quote

Ligand Pharmaceuticals (LGND) Initiated At 'Buy' By Brean Capital, PT $25

 January 04, 2013 02:03 PM
 


(By Balachander) Ligand Pharmaceuticals Inc. (NASDAQ: LGND) shares were initiated with a "Buy" rating and price target of $25 by Brean Capital LLC.

The brokerage said the rating is based on the NPV of its discounted cash flow forecast from the company's partnered assets.

LGND's valuation is primarily driven by royalty revenue from sales of GSK's Promacta in ITP and newly approved HCV indications, as well as licensing agreements related to LGND's Captisol, the brokerage wrote.

Brean estimates the peak royalty potential of Promacta in ITP and HCV to be in the $15-20M range on peak Promacta sales of about $300M.

[Related -Six Stocks That Could Get An October Bump From The FDA]

"However, GSK is also currently pursuing expansion of the Promacta label beyond ITP and HCV indications to include oncology, and we believe the launch of this indication could occur as early as 2017, with peak sales reaching $2.9B in various tumor settings," the brokerage said.

Brean said its long-term forecast for Promacta sales in 2024 reach $3.2B, which would generate royalty revenue of $292M to Ligand. The near-term value for Captisol will be driven from Kyprolis royalties, which the brokerage believes can reach $50M by 2015, with peak royalty of $150M in 2027.

Beyond Promacta and Captisol, LGND has a robust pipeline of partnered programs that include the anti-infective candidate delafloxacin with RIB-X, Captisol-enabled iv clopidogrel with Medicines Company and dinaciclib with Merck that offer upside to our current forecasts.

[Related -Futures Gain After Claims Data; Amazon.Com (AMZN) Drops]

LGND shares fell 4.65 percent to trade at $19.47 on Friday. Over the past year, the stock has been trading between $11.21. and $21.75.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChart Says This Retailer's Comeback Isn't Finished

One of the surprises, at least on the surface, of the market's recent swoon was the outperformance of read on...

article imageETF Performance Review: Major Asset Classes | 19 Dec 2014

It’s all about real estate investment trusts (REITs) these days when it comes to bullish performance among read on...

article imageOil and Global Stock Markets Rebounding Sharply

So far so good on our expectation of a 4 to 5% pullback and then a resumption of the bull read on...

article imageGrading the FOMC

Love its members or loathe them, you have to admire the gradual impact the policy-making committee has had read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.